STOCK TITAN

[Form 4] Avita Medical, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Positive)
Form Type
4
Rhea-AI Filing Summary

Avita Medical director Robert McNamara reported a personal purchase of company stock on 08/28/2025. The Form 4 shows a purchase of 10,000 shares of Avita Medical common stock at $4.50 per share. After the transaction he beneficially owns 86,771 shares, a figure the filing notes includes unvested restricted stock units. The filing identifies McNamara as a director and was signed by an authorized power of attorney on 08/29/2025. The document lists no derivative transactions and provides no additional financial results or forward-looking statements.

Robert McNamara, direttore di Avita Medical, ha dichiarato un acquisto personale di azioni della società in data 08/28/2025. Il Form 4 indica l'acquisto di 10.000 azioni ordinarie di Avita Medical al prezzo di $4,50 per azione. Dopo l'operazione detiene beneficiariamente 86.771 azioni, cifra che la comunicazione sottolinea include unità di azioni vincolate non ancora vestite. La dichiarazione identifica McNamara come direttore ed è stata firmata da un procuratore autorizzato il 08/29/2025. Il documento non riporta transazioni derivati né fornisce ulteriori risultati finanziari o affermazioni prospettiche.

Robert McNamara, director de Avita Medical, informó una compra personal de acciones de la compañía el 28/08/2025. El Form 4 muestra la adquisición de 10.000 acciones ordinarias de Avita Medical a $4,50 por acción. Tras la operación posee de forma beneficiaria 86.771 acciones, una cifra que la presentación señala incluye unidades de acciones restringidas no consolidadas. La presentación identifica a McNamara como director y fue firmada por un apoderado autorizado el 29/08/2025. El documento no enumera transacciones con derivados ni ofrece resultados financieros adicionales o declaraciones prospectivas.

Avita Medical 이사 로버트 맥나마라는 2025-08-28에 개인적으로 회사 주식을 매입했다고 보고했습니다. Form 4에는 Avita Medical 보통주 10,000주를 주당 $4.50에 매수한 것으로 기재되어 있습니다. 거래 후 그는 실질적으로 86,771주를 보유하고 있으며, 제출서류는 이 수치가 미확정(베스팅되지 않은) 제한주(RSU)를 포함한다고 명시합니다. 해당 서류는 맥나마라를 이사로 식별하며 2025-08-29에 권한 있는 대리인이 서명했습니다. 문서에는 파생상품 거래가 기재되어 있지 않으며 추가 재무실적이나 향후 전망에 관한 진술도 포함되어 있지 않습니다.

Robert McNamara, administrateur d'Avita Medical, a déclaré un achat personnel d'actions de la société le 28/08/2025. Le Form 4 indique l'achat de 10 000 actions ordinaires d'Avita Medical au prix de 4,50 $ par action. Après la transaction, il détient bénéficiairement 86 771 actions, un chiffre que le dépôt précise comprend des unités d'actions restreintes non acquises. Le dépôt identifie McNamara comme administrateur et a été signé par un mandataire autorisé le 29/08/2025. Le document ne mentionne aucune transaction sur produits dérivés et n'apporte aucun résultat financier supplémentaire ni déclaration prospective.

Avita Medical-Direktor Robert McNamara meldete am 28.08.2025 einen persönlichen Kauf von Unternehmensaktien. Das Form 4 weist den Kauf von 10.000 Stammaktien von Avita Medical zu je $4,50 aus. Nach der Transaktion besitzt er wirtschaftlich 86.771 Aktien, eine Zahl, bei der die Einreichung betont, dass sie nicht freigegebene Restricted Stock Units einschließt. Die Einreichung benennt McNamara als Direktor und wurde am 29.08.2025 von einem bevollmächtigten Vertreter unterschrieben. Das Dokument nennt keine Derivatetransaktionen und enthält keine weiteren finanziellen Ergebnisse oder zukunftsgerichteten Aussagen.

Positive
  • Director purchase recorded: Acquisition of 10,000 shares at $4.50 per share indicates an insider buy.
  • Transparent beneficial ownership disclosure: Filing states post-transaction ownership of 86,771 shares and clarifies inclusion of unvested RSUs.
Negative
  • None.

Insights

TL;DR: Director purchased 10,000 shares at $4.50, increasing reported beneficial holdings to 86,771 shares.

This Form 4 documents a routine insider purchase rather than a sale or option exercise. The purchase price of $4.50 per share and the post-transaction beneficial ownership number are explicit; the filing also clarifies that the total includes unvested RSUs, which affects voting and economic rights until vesting. For investors, insider purchases can signal confidence but the form alone does not quantify materiality relative to total outstanding shares or disclose intent beyond the transaction itself.

TL;DR: Reporting person is a director and reported acquisition via Form 4; filing was executed via power of attorney.

The filing correctly identifies the reporting person as a director and notes the Form 4 was signed by a named attorney-in-fact, which is standard practice. The inclusion of unvested RSUs in the beneficial ownership total is explicitly disclosed, which is important for governance transparency. The document contains no indication of related-party transactions, accelerated vesting, or amendments that would raise governance concerns.

Robert McNamara, direttore di Avita Medical, ha dichiarato un acquisto personale di azioni della società in data 08/28/2025. Il Form 4 indica l'acquisto di 10.000 azioni ordinarie di Avita Medical al prezzo di $4,50 per azione. Dopo l'operazione detiene beneficiariamente 86.771 azioni, cifra che la comunicazione sottolinea include unità di azioni vincolate non ancora vestite. La dichiarazione identifica McNamara come direttore ed è stata firmata da un procuratore autorizzato il 08/29/2025. Il documento non riporta transazioni derivati né fornisce ulteriori risultati finanziari o affermazioni prospettiche.

Robert McNamara, director de Avita Medical, informó una compra personal de acciones de la compañía el 28/08/2025. El Form 4 muestra la adquisición de 10.000 acciones ordinarias de Avita Medical a $4,50 por acción. Tras la operación posee de forma beneficiaria 86.771 acciones, una cifra que la presentación señala incluye unidades de acciones restringidas no consolidadas. La presentación identifica a McNamara como director y fue firmada por un apoderado autorizado el 29/08/2025. El documento no enumera transacciones con derivados ni ofrece resultados financieros adicionales o declaraciones prospectivas.

Avita Medical 이사 로버트 맥나마라는 2025-08-28에 개인적으로 회사 주식을 매입했다고 보고했습니다. Form 4에는 Avita Medical 보통주 10,000주를 주당 $4.50에 매수한 것으로 기재되어 있습니다. 거래 후 그는 실질적으로 86,771주를 보유하고 있으며, 제출서류는 이 수치가 미확정(베스팅되지 않은) 제한주(RSU)를 포함한다고 명시합니다. 해당 서류는 맥나마라를 이사로 식별하며 2025-08-29에 권한 있는 대리인이 서명했습니다. 문서에는 파생상품 거래가 기재되어 있지 않으며 추가 재무실적이나 향후 전망에 관한 진술도 포함되어 있지 않습니다.

Robert McNamara, administrateur d'Avita Medical, a déclaré un achat personnel d'actions de la société le 28/08/2025. Le Form 4 indique l'achat de 10 000 actions ordinaires d'Avita Medical au prix de 4,50 $ par action. Après la transaction, il détient bénéficiairement 86 771 actions, un chiffre que le dépôt précise comprend des unités d'actions restreintes non acquises. Le dépôt identifie McNamara comme administrateur et a été signé par un mandataire autorisé le 29/08/2025. Le document ne mentionne aucune transaction sur produits dérivés et n'apporte aucun résultat financier supplémentaire ni déclaration prospective.

Avita Medical-Direktor Robert McNamara meldete am 28.08.2025 einen persönlichen Kauf von Unternehmensaktien. Das Form 4 weist den Kauf von 10.000 Stammaktien von Avita Medical zu je $4,50 aus. Nach der Transaktion besitzt er wirtschaftlich 86.771 Aktien, eine Zahl, bei der die Einreichung betont, dass sie nicht freigegebene Restricted Stock Units einschließt. Die Einreichung benennt McNamara als Direktor und wurde am 29.08.2025 von einem bevollmächtigten Vertreter unterschrieben. Das Dokument nennt keine Derivatetransaktionen und enthält keine weiteren finanziellen Ergebnisse oder zukunftsgerichteten Aussagen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
McNamara Robert

(Last) (First) (Middle)
C/O AVITA MEDICAL 28159 AVENUE STANFORD
SUITE 220

(Street)
VALENCIA CA 91355

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
AVITA Medical, Inc. [ RCEL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/28/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/28/2025 P 10,000 A $4.5 86,771(1) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Includes unvested RSUs
/s/ Nicole Kelsey, by power of attorney 08/29/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Avita Medical director Robert McNamara report on Form 4 (RCEL)?

He reported purchasing 10,000 shares of Avita Medical common stock on 08/28/2025 at $4.50 per share and now beneficially owns 86,771 shares.

Does the filing indicate whether the 86,771 shares are fully vested?

No; the Form 4 explicitly states that the 86,771 total includes unvested restricted stock units (RSUs).

Was the Form 4 signed by Robert McNamara personally?

No; the signature block shows the form was signed by Nicole Kelsey by power of attorney on 08/29/2025.

Are there any derivative transactions reported in this Form 4?

No; the filing lists only a non-derivative purchase of common stock and no options, warrants, or other derivative securities.

What transaction date is listed on the Form 4?

08/28/2025 is shown as the transaction date for the purchase.
Avita Medical Inc

NASDAQ:RCEL

RCEL Rankings

RCEL Latest News

RCEL Latest SEC Filings

RCEL Stock Data

117.26M
26.39M
0.87%
29.13%
22.03%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
VALENCIA